首頁 > 市場調查報告書 > 製藥

非專利藥糖尿病生物製劑生技仿製藥

市場調查報告書

商品編碼

1593471

胰島素市場規模、佔有率、成長分析、按產品類型、輸送設備、按類型、按應用、按分銷管道、按地區：2024-2031年產業預測

Insulin Market Size, Share, Growth Analysis, By Product Type, By Delivery Device, By Type, By Application, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月10日 | 出版商:

SkyQuest | 英文 192 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球胰島素市場規模為206.8億美元，從2023年的209.9億美元成長到2031年的236.9億美元，年複合成長率預計為1.52%。

胰島素市場經歷顯著成長，這主要是由於全球糖尿病盛行率的上升和藥物開發的進步。據世界衛生組織（WHO）表示，糖尿病是世界上成長最快的慢性疾病之一，預計到2021年將有 5.37億成年人受到影響，因此對胰島素的需求將會增加。然而，針對第2 型糖尿病的新處方藥的推出，包括 GLP-1 受體促效劑（GLP-1 RA），可能會阻礙該成長軌跡。該市場仍被Novo Nordisk A/S、Sanofi和Eli Lilly and Company等主要企業寡占。此外，化學製造的進步在市場擴張中發揮重要作用。值得注意的創新包括Novo Nordisk的Fiasp（結合門冬胰島素和菸鹼醯胺以增加吸收）和 Mannkind 的Afrezza（第一個不需要針頭的吸入胰島素產品）。此外，Oramed Pharmaceuticals 推進口服胰島素膠囊的3期臨床試驗，預計在2023年底年終提交生技藥品核准申請（BLA）。隨著糖尿病治療隨著這些進步而發展，市場格局也必須跟上不斷變化的治療選擇和患者需求。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東、非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Eli Lilly and Company
Sanofi
Novo Nordisk A/S
Biocon
Boehringer Ingelheim International GmbH
Tonghua Dongbao Pharmaceutical Co. Ltd.
Wockhardt
Julphar
Novo Nordisk
Merck & Co., Inc.
Pfizer Inc.
AstraZeneca
Johnson & Johnson
Biocon Ltd.
Ypsomed AG
Gan & Lee Pharmaceuticals
Bioton SA
Adocia
Torrent Pharmaceuticals Ltd.
Ipsen
Dongbao Enterprise Group Co., Ltd.

簡介目錄

Product Code: SQMIG35A2943

Global Insulin Market size was valued at USD 20.68 billion in 2022 and is poised to grow from USD 20.99 billion in 2023 to USD 23.69 billion by 2031, growing at a CAGR of 1.52% during the forecast period (2024-2031).

The insulin market is experiencing significant growth, primarily driven by the rising global prevalence of diabetes and progress in drug development. With diabetes being one of the fastest-growing chronic diseases worldwide-affecting an estimated 537 million adults in 2021 according to the World Health Organization-the demand for insulin continues to rise. However, the introduction of GLP-1 receptor agonists (GLP-1 RAs) and other novel prescription medications for type 2 diabetes may hinder this growth trajectory. The market remains largely oligopolistic, with key players such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company dominating the landscape. Additionally, advancements in chemical manufacturing are playing a critical role in market expansion. Notable innovations include Fiasp by Novo Nordisk, which combines insulin aspart with niacinamide to enhance absorption, and Afrezza by Mannkind, the first inhaled insulin product that eliminates the need for needles. Furthermore, Oramed Pharmaceuticals is progressing with Phase 3 clinical trials for its oral insulin capsules and is anticipated to file a Biologics License Application (BLA) by the end of 2023. As the diabetes treatment landscape evolves with these advancements, the insulin market must adapt to keep pace with changing therapeutic options and patient needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insulin Market Segmental Analysis

Global Insulin Market is segmented by Product Type, Delivery Device, Type, Application, Distribution Channel, and Region. Based on Product Type, the market is segmented into Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar, Others. Based on Delivery Devices, the market is segmented into Pens, Infusion Pumps, Syringes, and Others. Based on Type, the market is segmented into Human Insulin, Insulin Analog. Based on Application, the market is segmented into Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insulin Market

The global insulin market is significantly propelled by the escalating prevalence of diabetes, driven by factors such as sedentary lifestyles, unhealthy dietary choices, and rising obesity rates. As these lifestyle changes lead to higher incidences of both type 1 and type 2 diabetes, there is a growing demand for insulin therapies to effectively manage blood glucose levels. This surge in the patient population, especially in densely populated regions like Asia and Africa, highlights the urgent need for both traditional and innovative insulin solutions. Consequently, healthcare providers and pharmaceutical companies are increasingly focusing on developing advanced insulin formulations to meet the needs of this expanding market.

Restraints in the Global Insulin Market

A significant market restraint for the global insulin market is the high cost associated with insulin therapy, which disproportionately affects individuals in regions with limited healthcare access. The price of advanced insulin analogs, which offer improved efficacy and convenience, can be prohibitively expensive, restricting availability for low-income patients. This financial barrier is especially pronounced in developing countries, where inadequate or nonexistent healthcare reimbursement systems further exacerbate the issue, leading to substantial gaps in essential diabetes management. As a result, many patients may be forced to forgo necessary treatments, ultimately impeding market growth and diminishing health outcomes for those affected by diabetes.

Market Trends of the Global Insulin Market

The global insulin market is experiencing a significant shift towards biosimilar insulin, driven by the expiration of mainstream insulin patents and the push for cost-effective alternatives. Regulatory bodies like the European Medicines Agency (EMA) and the U.S. FDA are facilitating the approval process for biosimilars, effectively enhancing market competition and reducing prices. This trend is expected to not only lower medical costs for patients but also improve access to insulin in high-cost markets, fostering a more inclusive healthcare environment. As healthcare systems prioritize affordability and accessibility, the biosimilar insulin segment is poised to drive substantial growth in the global insulin market.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Patent Analysis
Regulatory Landscape
PESTEL Analysis
Pipeline Analysis
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition
Customer & Buying Criteria Analysis

Insulin Market by Product Type

Market Overview
Rapid-Acting Insulin
- Insulin Lispro
- Insulin Lispro
- Insulin Glulisine
- Technosphere insulin
Long-Acting Insulin
- Insulin Detemir
- Insulin Glargine
- Insulin Glargine-yfgn
- Insulin Degludec
Combination Insulin
- NPH/Regular
- Protamine/Lispro
- Protamine/Aspart
Biosimilar
Others

Insulin Market by Delivery Device

Market Overview
Pens
Infusion Pumps
Syringes
Others

Insulin Market by Type

Market Overview
Human Insulin
Insulin Analog

Insulin Market by Application

Market Overview
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Insulin Market by Distribution Channel

Market Overview
Hospitals
Retail Pharmacies
Others

Insulin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tonghua Dongbao Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wockhardt
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Julphar
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ypsomed AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gan & Lee Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioton S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adocia
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Torrent Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dongbao Enterprise Group Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments